A randomized, double-blind, comparative, parallel-group, multicentre trial to evaluate the safety and efficacy of 1592U89 versus placebo in combination with background antiretroviral therapy in HIV-infected antiretroviral therapy experienced subjects with CD4+ cell counts ≥ 100cells/mm³ and plasma viral load between 400 copies/ml and 50 000 copies/ml 1997
Phase I, placebo-controlled study of oral BCX-34 (Peldesine) 1998
Saquinavir SGC G5030 (Racing-Trial)
Pilot Study to evaluate the efficacy and safety of Saquinavir SGC in combination with Zidovudine and Zalcitabine and to optimize the sequence of two different antiviral triple regimes with respect to the development of resistance mutations in HIV-infected patients
A randomized, double-blind, phase III study of ABT-378/Ritonavir plus Stavudine and Lamivudine vs. Nelfinavir plus Stavudine and Lamivudine in antiretroviral-naive HIV-infected subjects 1999
A randomized, open-label, phase III study of ABT-378/Ritonavir in combination with Nevirapine and 2 nucleoside reverse transcriptase inhibitors (NRTIs) vs. Investigator selected protease inhibitor(s) in combination with Nevirapine and 2 NRTIs in antiretroviral-experienced HIV-infected subjects
A randomized double-blind comparison of MKC-442 versus placebo in antiretroviral-naive patients with HIV-1 RNA 5000 and 50000 copies/ml and CD4+ ³300 cells/mm³ who are initiating therapy with stavudine, lamivudine
Multizentrische, randomisierte, offene Phase III-Studie zum Vergleich der antiretroviralen Aktivität und Verträglichkeit drei verschiedener Kombinationstherapien bei HIV-infizierten Patienten (DMP-266 plus Indinavir, DMP-266 plus Zidovudin plus Lamivudin, Indinavir plus Zidovudin plus Lamivudin
Eine offene, randomisierte, multizentrische Studie der Phase II bei HIV-1 infizierten Patienten zur Bewertung der Sicherheit und Dauer der Virussuppression unter einer fortgesetzten Standardtherapie bestehend aus einem Protease-Inhibitor und zwei Nukleosidalen Reverse Transkriptase-Inhibitoren im Vergleich zu zwei neuen Therapieschemata, in denen entweder die Nukleosidalen Reverse Transkriptase-Inhibitoren oder der Protease-Inhibitoren durch DMP 266 ersetzt wird.
A randomized double-blind comparison of MKC-442 versus placebo in antiretroviral-naive patients with HIV-1 RNA >5000 and £300 000 copies/ml and CD4+ >300 cells/mm³ who are initiating therapy with stavudine, didanosine
An open-label extension study for patients on an emivirine containing regimen (roll over protocol for the MKC-301 and 302 being conducted in Europe)
A phase II randomised, multicenter, partially blinded, crossover study to assess the safety, tolerability, pharmacokinetics, and antiviral effect of two doses of GW433908 compared to Amprenavir (1200 mg bid) when given for 28 days to subjects infected with HIV-1
A multicenter, dose escalating study in patients with cutaneous AIDS-related Kaposi’s Sarcoma
A multicenter, open-Label, phase II study of the efficacy and saftety of SU5416 in patients with therapy refractory cutaneous AIDS-related Kaposi’s Sarcoma
Eine multizentrische, offene Phase III Studie zum Vergleich der antiretroviralen Aktivität, Verträglichkeit und Sicherheit von drei verschiedenen Kombinationstherapien bestehend aus: Efavirenz + Stavudine + Didanosin / Abacavir + NRTI + Lamivudin / Stavudin + Didanosin + Indinavir bei HIN-infizierten Patienten. Eine Folgestudie für die Studie DMP 266-006
GW433908 vs. amprenavir
Ersatztherapie nach dreifach kombinierter Induktionstherapie zur Verlängerung des Netto-Therapieeffektes durch Verzögerung der Resistenzentwicklung bei HIV-1 infizierten Patienten (multizentrische, randomisierte, open-label Studie).
A phase III, multicenter, randomized trial on the biological and clinical efficacy of subcutaneous, recombinant human Interleukin-2 in HIV infected patients with low CD4+ count by active, antiretroviral therapy 2000
A randomized international, parallel group, open label comparison of the efficacy of second line antiretroviral therapy chosen based on best clinical judgment, or best clinical judgment plus HIV resistence genotyping supported by HIV Resistance Support Software interpretation, in HIV infected patients failing their first protease containing regime.
GF 9037 (Serostim)
A randomized, parallel group, double-blind, placebo-controlled, dose-ranging, multicenter study of recombinant human growth hormone (Serostim) in the treatment of HIV associated catabolism/wasting
A phase II, randomized, double-blind, dose-ranging study to assess the safety and tolerability of three doses of DPC 083 versus Efavirenz, in combination with open-label Zidovudine and Lamivudine, in antiretroviral-naive, HIV-1-infected subjects
A phase III randomized, double-blind, multicenter study of the treatment of antiretroviral-naive, HIV-1-infected patients comparing with Lamivudine and Efavirenz versus Stavudine, Lamivudine and Efavirenz
Comparative pharmacokinetics of twice-daily saquinavir administered as the soft gel capsule formulation or the hard gel capsule formulation in combination with ritonavir
A randomized, open label two arm trial to compare the safety und antiviral efficacy of GW 433908/Ritonavir to Nelfinavir BID when used in combination with Abacavir and Lamivudine BID for 48 weeks in antiretroviral therapy naive HIV-1 infected subjects
A randomized, double-blind, equivalence trial comparing Emtricitabine to Stavudine with a triple drug combination containing Didanosine plus Efavirenz in antiretroviral drug naive HIV-1 infected patients 2001
TORO 1 / TORO 2 RO 29-9800 T20-302/BV 16052
A phase III open-label, randomized, active, controlled study assessing the efficacy and saftey of T20 / Ro 29-9800 (HIV-1 fusion inhibitor) in combination with an optimized background regimen, versus optimized background regimen alone, in patients with prior experience and/or prior documented resistance to each of the three classes of approved antiretrovirals (nucleoside reverse transciptase inhibitors, non-nucleosids reverse transcriptase inhibitors and protease inhibitors)
BI 1182.6 (Tipranavir)
A phase IIa open-label multinational study of the effects of three dose pairs of Tipranavir/Ritonavir (b.i.d.) on the pharmacokinetic characteristics of protocol-defined, baseline, triple drug nucleoside and non-nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected subjects.
A Phase II randomized, double-blind, multicenter study to assess the safety and efficacy of two doses of DPC 083, in combination with open-label Nucleoside Analog Reverse Transcriptase Inhibitors in HIV-1–infected subjects who are failing treatment with a non-nucleoside reverse transcriptase inhibitor-containing regimen
A phase III, randomized, multicenter, parallel group, open-label, three arm study to compare the efficacy and safety of two dosing regimes of GW433908/Ritonovir (700mg/100 mg twice daily or 1400mg/200mg once daily) versus Lopinavir/Ritonavir (400mg/100mg twice daily) for 48 weeks in protease inhibitor experienced HIV-infected Adults experiencing virological failure
CNA 30021 (Zodiac)
A phase III, 48-week, randomised, double-blind, multicenter study to evaluate the safety and efficacy of Abacavir 600 mg once-daily (QD) vs. Abacavir 300 mg BID in combination with Lamivudine 300 mg QD and Efavirenz 600 mg QD in antiretroviral therapy naive HIV-1 infected subjects
Efficacy of an 8-day treatment (7 days b.i.d. and 1 day o.d.) with 900mg TMC125 in HIV-1 positive subjects with phenotypically confirmed NNRTI resistance
GS-00-951 (Tenofovir EAP)
Eine offene Phase IIIb Studie zur Sicherheit und Verträglichkeit von Tenovovir Disoproxil Fumarat bei der Behandlung von HIV-infizierten Patienten mit begrenzten Behandlungsmöglichkeiten
BI 1100. 1359
Investigation of pharmacokinetic interaction of nevirapine and Methadon in HIV-infected patients under combination treatment with various NRTIs, phase IV
A phase IIa open, randomized trial to determine the antiviral activity in 60 HIV positive subjects with multiple PI resistant strains, receiving either control treatment or a daily dose of 800, 1600, 2400 or 3600 mg for 13 days followed by a single dose on day 14
A phase-IIa repeat dose-rising study to explore the safety, efficacy and pharmakokinetics of intravenous AXD 455 doses in HIV-infected patients with multi-resistance or intolerable side effects on haart
A Phase III, randomized, double-blind, multicenter study to acess the safety and efficacy of DPC 083 versus Nelfinavir in combination with AZT/3TC (i.e. Zidovudine and Lamivudine) in antiretroviral-naive HIV‑1‑infected subjects
A randomized, placebo-controlled phase II trial in HIV-1 infected, NRTI-, PI- and NNRTI-experienced subjects to evaluate the safety, tolerability and efficacy of different doses of TMC125 b.i.d. on top of an individually optimized antiretroviral therapy by means of a 3-stage dose-escalating design 2002
BI 1182.52 (Tipranavir)
A phase IIb double-blind, randomized, dose optimization trial of three doses of Tipranavir boosted with low dose Ritonavir (TPV/RTV) in multiple antiretroviral drug-experienced subjects.
A phase IIa open, randomized trial to determine the antiviral activity in HIV-1 positive subjects with multiple PI resistant strains, receiving either control treatment or TMC 114/Ritonavir treatment at various dosages for 13 days followed by a single dose on day 14
Klinische Prüfung der Phase 3 zu PEG-Intron bei intensiv behandelten HIV infizierten Patienten
A phase I study exploring the safety, tolerability, pharmacokinetics and virological effect of RCV after 14 days of oral ascending doses of 200, 400 and 600 mg RCV when used in combination with Efavirenz and Stavudine in HIV-infected men
An open-label phase III study to assess the long term safety profile of GW33908 containing regimens in HIV-1 infectect subjects
BI 1182.48 (RESIST-2)
Randomized, open-label, comparative safety and efficacy study of Tipranavir boosted with low-dose Ritonavir versus genotypically-defined Protease Inhibitor/Ritonavir in multiple antiretroviral drug-experienced patients (RESIST 2: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients with Tipranavir) 2003
A long-term open-label roll-over trial assessing the safety and tolerability of combination Tipranavir and Ritonavir use in HIV- infected subjects
An open label, randomized, parallel group pharmacokinetics trial of tipranavir / ritonavir (TPV/TRV), alone or in combination with RTV-boosted saquinavir (SQV), amprenavir (APV) or lopinavir (LPV), plus an optimized background regimen, in multiple antiretroviral (ARV) experienced patients
Simultaneous boosting of Nelfinavir and Saquinavir by small doses of Ritonavir: a pharmakokinetic study in HIV-infected patients
A phase II randomized, controlled (standard of care), partially blinded, 48-week trial to investigate dose response of TMC114/rtv in 3-class-experienced HIV-infected subjects 2004
An open-label trial of TMC114/rtv in HIV-1 infected, treatment experienced subjects
A phase IIb/III randomised, open label, active controlled trial to evaluate the antiviral efficacy and safety of treatment with 500 mg Tipranavir plus 100 mg or 200 mg Ritonavir p.o. BID in combination with standard background regimen in comparison to 400 mg Lopinavir plus 100 mg Ritonavir p.o. BID in combination with standard background regimen in antiretroviral therapy naïve patients for 48 weeks
INCB 8721 RVT-203 (Reverset)
A phase II placebo-controlled, double-blind, parallel dose group study exploring the safety, tolerability and virological effect of 50, 100 and 200 mg RVT in HIV-infected antiretroviral therapy-experienced subjects when used in combination with other antiretroviral agents
A phase II, proof of principle, randomized, open-label trial in HIV-infected subjects with NNRTI experience and/or genotypic evidence of NNRTI resistance, who will receive R27874 once daily for 7 days in substitution for the NNRTI or PI in failing ART
A Phase I ,open-label, randomized, single dose, cross-over study to evaluate the relative bioavailability of 3 dose levels of TMC125 in HIV-1 infected subjects as a spray-dry formulation compared to the reference formulation TF035.
INCB 8721 DFC-901 (Reverset r-o)
A long-term open-label non-randomized study to evaluate the safety of 100 and 200 mg ReversetTM (RVT) in HIV-infected antiretroviral therapy-experienced subjects when used in combination with other antiretroviral agents 2005
A multicenter, randomized, double-blind, placebo-controlled trial of a novel CCR5-antagonist, UK-427,857, in combination with OBT versus OBT alone for the treatment of antiretroviral-experienced HIV-1-infected subjects
A multicenter, randomized, double-blind, placebo-controlled trial of a novel CCR5-antagonist, UK-427,857, in combination with OBT versus OBT alone for the treatment of antiretroviral-experienced non CCR5-tropic HIV-1-infected subjects
A Phase IIb, 96 week, randomized, partially double-blinded, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW 873140 in combination with AZT/3TC (Lamivudine + Zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naïve adults
A Phase I randomized, open-label, multiple dose, cross-over trial in HIV-1 infected subjects to evaluate the relative bioavailability of TMC125 as a spray-dry formulation compared to the reference formulation TF035
A phase IIb randomized, partially blinded, dose-finding trial of TMC278 in antiretroviral naïve HIV-1 infected subjects. EudraCT No. 2004-004055-19.
An open label trial of TMC114/rtv in HIV-1 infected subjects who were randomized in the trials TMC114-C201, -207 or in sponsor selected phase-I-trials
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. EudraCT No. 2005-000594-22
An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks
TMC125-C216 (DUET 2)
A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects with limited to no treatment options. [IND No. 63646] – A substudy of TMC125-C216 to evaluate the pharmacokinetic profile of TMC125, TMC114 and RTV at Week 4 and 24, co-administered with an individually optimized antiretroviral therapy 2006
An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216)
TMC 114-C211 (ARTEMIS)
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/Ritonavir versus Lopinavir/Ritonavir in treatment-naive HIV-1 infected subjects. This trial will be referred to as ARTEMIS. EudraCT No. 2005-002486-36
AI 424-138 (CASTLE)
A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment Naïve Subjects
A Case-Control Toxicogenomics Study to Identify Genetic Locus or Loci in Patients who have Experienced Symptomatic Hepatotoxicity and Severe Skin Rash within the First 8 weeks of Nevirapine Therapy. EudraCT No. 2005-004321-26
A multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and antiretroviral activity of MK-0518 in combination with an optimized background therapy (OBT) versus optimized background therapy alone, in HIV Infected patients with documented resistance to at least 1 drug in each of the 3 classes of licensed oral antiretroviral therapies. EudraCT No. 2005-005127-34.
BI 1100.1470 (ARTEN)
Open-label, randomised clinical trial to compare the virological efficacy and safety of Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine vs. Nevirapine on same background, in HIV-1-infected patients who have received no previous antiretroviral treatment. EudraCT No. 2005-004330-40.
A randomized, double blind, two-armed trial to evaluate the efficacy and safety of MK-0518 versus LPV/RTV in patients with maximum suppression with LPV/RTV 2007
BI 1100.1498 (ERVIR)
Steady State Bioavailability of 2 different Viramune Extended Release formulations compared to steady state 400 mg of Viramune (200 mg BID) in HIV infected subjects, an open label, non randomized, multidose and multistage parallel group study.
A 14-Day, Randomized, Double-blind, comparative viral kinetic study of Elvucitabine versus Lamivudine administered once daily to HIV-1 infected subjects with a documented M184V variant
An open-label, 24-week extension study of Elvucitabine administered in combination with background antiretroviral agents in subjects who have completed 14 days of treatment in protocol ACH443-014A 2008
A multicenter, randomized, open label, clinical trial to evaluate three doses of tipranavir boosted with ritonavir (500 mg/200 mg qd, 250 mg/100 mg bid and 500 mg/100 mg bid) by assessing the steady-state pharmacokinetics and short-term efficacy and Safety in HIV-1 positive treatment naïve patients
BI 1100.1486 (Verxve)
A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD Nevirapine extended release formulation in comparison to 200 mg BID antiretroviral therapy naïve HIV-1 infected patients. EudraCT No. 2007-003654-29.
Safety, antiviral activity and pharmacokinetics of multiple oral doses of BI 207127 NA administered q8H for 5 days as monotherapy: a randomised, double-blind, placebo controlled study. EudraCT No. 2007-004068-38.
A phase 2b/3, randomized, double blind, dose confirming study of the safety, efficacy and tolerability of Apricitabine versus Lamivudine in treatment-experienced HIV-1 infected patients with the M184V/I mutation in reverse transcriptase. EudraCT No. 2007-003281-18.
TMC 278-TiDP6-C215 (Thrive)
A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus Efavirenz 600 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral-naïve HIV-1 infected subjects. EudraCT No. 2007-002647-25.
BI 1100.1526 (Tranxition)
An open label, phase IIIb, randomized parallel group study to assess the efficacy and safety of switching HIV-1 infected patients successfully treated with a Nevirapine IR based regimen to Nevirapine XR 400 mg QD or remaining on Nevirapine IR 200 mg BID based regimen. EudraCT No. 2008-004681-55.
Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 24 weeks as combination therapy with pegylated interferon-α 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II). EudraCT No. 2008-003538-11.
112353 (TH-HIV-010 PRI)
A Phase I, randomised, placebo controlled, observer blind, multicentre study to determine safety and reactogenicity of F4co/AS01B vaccine, administered intramuscularly according to a 0, 1 Month schedule in HIV-infected subjects aged 18-55 years. EudraCT No. 2008-005009-20. 2009
CT-BI Vacc-4x 2007/1
A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART. EudraCT No. 2007-006302-13.
Pilot Study of novel Combination of Maraviroc + Atazanavir/Ritonavir vs Atazanavir/Ritonavir + Tenofovir/Emtrici- tabine for the treatment of Treatment naive HIV-infected patients with R5 HIV-1. EudraCT No. 2008-007038-24.
A Phase IIa, open-label, randomized trial in treatment-naive HIV-1-infected subjects to determine the antiviral activity of 14 days of monotherapy with 2 different b.i.d. dose regimens of TMC310911 co-administered with ritonavir. EudraCT No. 2008-008190-58
A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Ribavirin in Treatment-Experienced Patients with Chronic Genotype 1 Hepatitis C Virus Infection. EudraCT No. 2008-000150-12.
Safety, antiviral activity, and pharmacokinetics of BI 207127 NA administered in combination with Peg-IFN and ribavirin in chronic HCV infected patients for 4 weeks, a randomised, double-blind, placebo controlled study. EudraCT No. 2008-008292-34.
A Phase IIb, randomized double-blind, placepo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including peginterferon alfa-2a and ribavirin in treatment-naïve genotype 1 hepatitis C-infected subjects. EudraCT No. 2008-007147-13.
A Phase IIb, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including PegIFNα-2a and ribavirin in HCV genotype 1 infected subjects who failed to respond or relapsed following at least 1 course of PegIFNα-2a/b and RBV therapy. EudraCT No. 2009-010590-20.
BI 1241.21 (SOUND)
Safety, antiviral effect and pharmacokinetics of BI 207127 incombination with BI 201335 and with ribavirin for 4 (Part 1) and with or without ribavirin for 24-48 weeks (Part 2) in patients with chronic HCV genotype 1 infection (randomized, open label, Phase II). EudraCT No. 2009-018197-66
(Filibuvir in Treatment Naïve HCV Genotype 1 Subjects) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Filibuvir Plus Pegylated Interferon Alfa-2a and Ribavirin in Treatment naïve, HCV Genotype 1 Infected Subjects. EudraCT No. 2009-009214-40 2010
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. EudraCT No. 2009-016759-22
A prospective 1-year virological follow-up study in subjects previously treted in Phase IIb or Phase III study with a TMC435-containing regimen for the trearment of hepatitis C virus (HCV) infection. 2011
An open-label trial with TMC275 25mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide revers transcriptase inhibitors in HIV-1 infected subjects, who partici- pated in TMC278 clinical trials. EudraCT No.: 2010-021209-18
A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/ lamivudine fixed dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naïve aduld subjects. EudraCT No. 2010-020983-39
A Phase 3 Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically-Suppressed, HIV-1 Infected Patients. EudraCT No. 2010-023178-37
Efficacy and safety of once daily BI 201335 for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in treatment naïve patients with genotype 1 chronic hepatitis C infection (double-blinded, randomised, placebo-controlled, Phase III). EudraCT No. 2010-021716-42
A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 for 24 weeks in combination with pegylated interferon-α and ribavirin in patients who failed to a prior PegIFN / RBV treatment with genotype 1 chronic hepatitis C infection. EudraCT No.: 2010-021715-17
A Multicenter, Randomized, Blinded, Placebo-Controled Study to evaluate the Safesty of Maraviroc in Combination with other Antiretroviral Agents in HIV-1-Infected Subjects Co-Infected with Hepatitis C and/or Hepatitis B Virus. EudraCT No. 2010-021994-35
A phase III, open-label, study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN / RBV treatment. EudraCT No.: 2011-000347-25
A Phase 3B, Randomized, Open-label Study to Evaluate theSafety and Efficacy of a Single Tablet Regimen of Emtricitabine/ Rilpivirine/Tenofovir Disoproxil Fumarate Compared with a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. EudraCT No. 2010-024007-27
Safety and Efficacy of 240 mg BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic Hepatitis C (HCV) genotype 1 infection in HIV/HC V-co-infected patients. A multinational, randomised, parallel group, open-label trial. EudraCT No.: 2010-021734-59
A Phase IIb Randomized, Controlled, Partially Blinded Trial to Investigate Safety, Efficacy and dose-response of BMS-663068 in Treatment-experienced HIV-1Subjects, Followed by an Open-label Period on the Recommended Dose. EudraCT No.: 2011-000437-36
Multizentrische, randomisierte, doppelblinde Vergleichsstudie zu Maraviroc und Darunavir/Ritonavir versus Emtricitabin/ Tenofovir + Darunavir/Ritonavir zur Behandlung nicht antiretroviral vorbehandelter HIV-Patienten mit CCR5-tropem HIV-1. EudraCT No.: 2010-021785-30
A Phase I, open label trial in genotype 1 HCV-infected subjects to determine the safety, tolerability, pharmacokinetics and antiviral activity of repeated doses of TMC647055 given in combination with telaprevir. EudraCT No.: 2011-004028-37 2012
A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients. 2011-004483-30
A Phase 3 Study with Asunaprevir and Daclatasavir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligibleto P/R Subjects and Treatment-Naive Subjects with Chronic Hepatitis C Genotype 1b Infection. EudraCT No.: 2011-005446-35
Randomized, Double-blind Placebo Controlled, Multicenter, Immunogenicity Pilot Study of Vacc-4x + Revlimid Versus Vacc-4x in Subjects Infected with HIV-1, on Antiretroviral Therapy (ART). EudraCT No.: 2011-001217-13
CT-BI Vacc-4x 2012/1
Re-boosting of Subjects Previously Included in the Phase IIB Study. An Open, Multicenter, Immunogenicity, Follow-up Re-boosting Study with Vacc-4x in Subjects Infected with HIV-1 Who Have Maintained an Adequate Response to ART. EudraCT No. 2012-002281-12
A Phase 3b Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically-Suppressed, HIV-1 Infected Patients EudraCT No.: 2011-004963-56
Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK- 1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients. EudraCT No.: 2012-001573-93
A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype 1 chronic hepatitis C infection. EudraCT No. 2012-003534-17 2013
A phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naive Patients with Chronic Genotype 1 HCV Infection. EudraCT No.: 2012-03533-41
A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects. EudraCT No.: 2012-005114-20
A Phase IIa, open-label trial to evaluate the safety, tolerability and efficacy of a 12 weeks combination therapy of TMC647055 and TMC435, with and without GSK2336805, with a pharmacokinetic enhancer with and without ribavirin in chronic genotype 1 hepatitis C infected patients. EudraCT No. 2012-002555-42 2014
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily Versus Raltegravir (MK-0518) 400 mg Twice Daily, Each in Combination With TRUVADA™, in Treatment-Naïve HIV-1 Infected Subjects. EudraCT No.: 2013-001939-47
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection. EudraCT-No.2014-001682-27
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV. EudraCT-No. 2014-001683-35
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection.EudraCT-No. 2014-003898-42 2015
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/ Emtricitabine/ Tenofovir Alafenamide Versus Abacavir/Dolutegravir/ Lamivudine in HIV-1 Infected Antiretroviral Treatment-Naïve Adults. EudraCT No.: 2016 2015-004024-54 2016
MK 3682-011 C-Crest
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1, GT2, and GT4 Infection. EudraCT-No.: 2014-003304-73
A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-,NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed. EudraCT No.: 2014-005148-16
A Phase 2b Randomized, Active-Controlled, Double-blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults. EudraCT No.: 2013-005487-26
A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/ tenofovir alafenamide once-daily single-tablet regimen versus a regimen consisting of darunavir/cobicistat fixed dose combination combined with emtricitabine/tenofovir disoproxil fumarate fixed dose combination in antiretroviral treatment-naïve human immunodeficiency virus type 1 infected subjects. EudraCT No.: 2015-000754-38
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) plus a Third Antiretroviral Agent to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV‑1 Infected Adult Subjects. EudraCT No.: 2015-002711-15
A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults. EudraCT No.: 2015-004011-20
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed. EudraCT No.: 2015-004025-14
Letzte Änderung: 18.03.2019